Novartis Ag

Arrowhead Pharmaceuticals, Inc.

Michael Ray Schlabach, Jr

Frank Peter Stegmeier

Stuart Milstein

Brian R Bettencourt

David A Bumcrot

Satyanarayana Kuchimanchi

Jan Weiler

Markus Warmuth

Dieter Huesken

Eric Billy

William Raj Sellers

Francesco Hofmann

Tobias Schmelzle

Gregory Hoffman

Konstantinos John Mavrakis

Earl Robert McDonald, Iii

Antoine De Weck

Javad Golji

Audrey Kauffmann

The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

Compositions and methods to treat cancer

The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.

Organic compositions to treat beta-catenin-related diseases

Growing community of inventors

Cambridge, MA, United States of America

Michael Ray Schlabach, Jr